PubRank

Michael von Wagner

Author PubWeight™ 18.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 2.62
2 IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006 2.54
3 Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011 2.40
4 Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006 1.49
5 Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004 1.44
6 Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011 1.39
7 International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005 1.30
8 HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007 1.06
9 Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir Ther 2006 0.89
10 Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol 2004 0.88
11 Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin. Eur J Gastroenterol Hepatol 2010 0.87
12 Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir Ther 2007 0.81
13 Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PLoS One 2013 0.76
14 Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. Dig Liver Dis 2010 0.75
15 Lack of birth defects after paternal exposure to lamivudine. J Hepatol 2002 0.75
16 Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C. Antivir Ther 2013 0.75